DAL MASO, ALESSANDRO

DAL MASO, ALESSANDRO  

Università di Padova  

Mostra records
Risultati 1 - 20 di 31 (tempo di esecuzione: 0.029 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257) 2025 Pasello, GiuliaPigato, GiuliaLando, StefaniaPotente, SaraRomualdi, ChiaraMaso, Alessandro DalBonanno, LauraGuarneri, ValentinaIndraccolo, Stefano + JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH - -
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer 2025 Dal Maso, AlessandroMinuzzo, Sonia AnnaPezzuto, FedericaZulato, ElisabettaPasello, GiuliaCalabrese, FiorellaFassan, MatteoRea, FedericoGuarneri, ValentinaIndraccolo, StefanoBonanno, Laura + FRONTIERS IN ONCOLOGY - -
MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial 2025 Bonanno, LauraDal Maso, Alessandro + CLINICAL CANCER RESEARCH - -
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis 2024 Pasello, GiuliaPavan, AlbertoDal Maso, AlessandroBonanno, LauraGuarneri, Valentina + FRONTIERS IN ONCOLOGY - -
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 2024 Bonanno, LauraZingone, FabianaBarberio, BrigidaDal Maso, AlessandroPasello, GiuliaDei Tos, Angelo PaoloFassan, MatteoSavarino, Edoardo VincenzoGuarneri, Valentina + THE ONCOLOGIST - -
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World 2024 Pasello, GiuliaPavan, AlbertoPolo, ValentinaBonanno, LauraDal Maso, AlessandroGuarneri, Valentina + THE ONCOLOGIST - -
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis 2024 Bonanno, LauraDal Maso, AlessandroPavan, AlbertoPasello, GiuliaGuarneri, Valentina + FRONTIERS IN IMMUNOLOGY - -
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer 2024 Maso, Alessandro DalBonanno, LauraGuarneri, ValentinaPasello, Giulia + CANCER TREATMENT REVIEWS - -
The role of liver kinase B1 in small cell lung cancer: association with prognosis and tumor immune microenvironment features 2024 DAL MASO, ALESSANDRO - - -
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients 2024 Bonanno, LauraDal Maso, AlessandroGuarneri, ValentinaPasello, Giulia + FRONTIERS IN IMMUNOLOGY - -
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 2023 Maso, Alessandro DalBrambilla, MartaPaggio, AngelaPasello, Giulia + JOURNAL OF THORACIC ONCOLOGY - -
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience 2022 Dal Maso, ADel Bianco, PNardo, GZulato, EBonanno, LPasello, GIndraccolo, S + JOURNAL OF THORACIC DISEASE - -
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 2022 Bonanno, LauraDal Maso, AlessandroZulato, ElisabettaPasello, GiuliaGuarneri, ValentinaConte, PierFrancoIndraccolo, Stefano + BRITISH JOURNAL OF CANCER - -
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments 2022 Sepulcri, MatteoSchiavon, MarcoMancin, EdoardoLunardi, FrancescaDal Maso, AlessandroBonanno, LauraCalabrese, FiorellaRea, FedericoGuarneri, ValentinaPasello, Giulia + CANCERS - -
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 2021 Dal Maso, A.Ferro, A.Pretelli, G.Frega, S.Menis, J.Pasello, G.Guarneri, V.Conte, P. F.Bonanno, L. + JOURNAL OF THORACIC ONCOLOGY - -
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 2021 Lorenzi, M.Dal Maso, A.Ferro, A.Scattolin, D.Indraccolo, S.Frega, S.Menis, J.Bonanno, L.Guarneri, V.Conte, P. F.Pasello, G. + JOURNAL OF THORACIC ONCOLOGY - -
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 2021 Bonanno, L.Dal Maso, A.Zulato, E.Fassan, M.Pasello, G.Guarneri, V.Calabrese, F.Rea, F.Indraccolo, S.Conte, P. F. + JOURNAL OF THORACIC ONCOLOGY - -
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors 2021 Marra, LudovicaBonanno, LauraBoscolo, AliceDal Maso, AlessandroBoscolo Bragadin, AndreaIndraccolo, StefanoZulato, Elisabetta + FRONTIERS IN ONCOLOGY - -
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 2021 Lorenzi, MartinaFerro, AlessandraScattolin, DanielaDal Maso, AlessandroIndraccolo, StefanoCalabrese, FiorellaBonanno, LauraConte, PierFrancoGuarneri, ValentinaPasello, Giulia + THE ONCOLOGIST - -
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 2021 Dal Maso, ALorenzi, MFerro, AScattolin, DIndraccolo, SFrega, SMenis, JBonanno, LCalabrese, FGuarneri, VConte, PPasello, G + FUTURE ONCOLOGY - -